Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Imipenem→

Imipenem Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
64221-86-9
Molecular formula
C12H17N3O4S
Molecular weight
299.35 g/mol
Drug class
Carbapenem beta-lactam antibacterialused clinically with cilastatin
Mechanism of action
Binds penicillin-binding proteins and inhibits bacterial cell-wall peptidoglycan synthesis, producing bactericidal activity. Cilastatin inhibits renal dehydropeptidase-I and prevents renal metabolism of imipenem; the fixed combination is used for systemic antibacterial therapy.
Indications / reported uses
  • Treatment of serious infections caused by susceptible bacteria, including selected intra-abdominal, lower respiratory-tract, urinary-tract, gynaecological, skin/soft-tissue, bone/joint and septicaemia infections; current local antimicrobial guidance and susceptibility testing apply

Sources: US DailyMed — Imipenem/cilastatin · NLM MeSH — Imipenem · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Imipenem Environmental Risk Assessment (ERA) (the Imipenem ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.